Education
About Us
Working with TipRanks
Follow Us
Wuxi Biologics (Cayman) (HK:2269)
:2269
RESEARCH TOOLSreports
2269 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$10.14 - HK$29.15
Previous CloseN/A
Volume35.71M
Average Volume (3M)72.84M
Market Cap
HK$78.96B
Enterprise ValueHK$69.84B
Total Cash (Recent Filing)¥9.67B
Total Debt (Recent Filing)¥4.56B
Price to Earnings (P/E)22.4
Beta1.76
Next Earnings
Aug 25, 2025EPS Estimate
0.48Last Dividend Ex-Date
Nov 02, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)0.89
Shares Outstanding4,108,316,000
10 Day Avg. Volume111,218,862
30 Day Avg. Volume72,843,159
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)14.68
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$31.57Price Target Upside64.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
---
Wuxi Biologics (Cayman) News
PremiumCompany Announcements
Wuxi Biologics Grants Over 25 Million Restricted Shares to Employees
PremiumCompany Announcements
Wuxi Biologics Reports Strong 2024 Earnings Growth
PremiumCompany Announcements
WuXi Biologics to Present 2024 Annual Results via Conference Calls
PremiumCompany Announcements
WuXi Biologics Schedules Board Meeting for Annual Results Approval---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceWuXi Biologics reported impressive results with a 9.6% increase in revenue and a 9.0% rise in adjusted net profit, indicating strong company performance.
Market PositionWuXi Biologics is a leading biologics CXO in China with a 13% global market share and 70% market share in China.
Operational ExpansionThe company has expanded its services overseas, reducing reliance on China and increasing its global footprint.
Bears Say
Political UncertaintyThere is a higher likelihood of the Biosecure Act being implemented due to a shift in political power, which adds uncertainty to WuXi Biologics' future operations in the US market.
Regulatory RisksThe Biosecure Act poses a significant threat to WuXi Biologics as it could ban US companies from dealing with the firm by 2032, affecting over half of its business.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
5.64%
Mutual Funds
0.02% Other Institutional Investors
87.50% Public Companies and
Individual Investors
2269 FAQ
What was Wuxi Biologics (Cayman) ’s price range in the past 12 months?
Wuxi Biologics (Cayman) lowest stock price was HK$10.14 and its highest was HK$29.15 in the past 12 months.
What is Wuxi Biologics (Cayman) ’s market cap?
Wuxi Biologics (Cayman) ’s market cap is HK$78.96B.
When is Wuxi Biologics (Cayman) ’s upcoming earnings report date?
Wuxi Biologics (Cayman) ’s upcoming earnings report date is Aug 25, 2025 which is in 135 days.
How were Wuxi Biologics (Cayman) ’s earnings last quarter?
Wuxi Biologics (Cayman) released its earnings results on Mar 25, 2025. The company reported HK$0.238 earnings per share for the quarter, missing the consensus estimate of HK$0.465 by -HK$0.227.
Is Wuxi Biologics (Cayman) overvalued?
According to Wall Street analysts Wuxi Biologics (Cayman) ’s price is currently Undervalued.
Does Wuxi Biologics (Cayman) pay dividends?
Wuxi Biologics (Cayman) pays a Notavailable dividend of HK$0.054 which represents an annual dividend yield of N/A. See more information on Wuxi Biologics (Cayman) dividends here
What is Wuxi Biologics (Cayman) ’s EPS estimate?
Wuxi Biologics (Cayman) ’s EPS estimate is 0.48.
How many shares outstanding does Wuxi Biologics (Cayman) have?
Wuxi Biologics (Cayman) has 4,108,316,000 shares outstanding.
What happened to Wuxi Biologics (Cayman) ’s price movement after its last earnings report?
Wuxi Biologics (Cayman) reported an EPS of HK$0.238 in its last earnings report, missing expectations of HK$0.465. Following the earnings report the stock price went down -1.708%.
Which hedge fund is a major shareholder of Wuxi Biologics (Cayman) ?
Currently, no hedge funds are holding shares in HK:2269
---
Wuxi Biologics (Cayman) Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$31.57 (64.23% Upside)
HK$31.57 (64.23% Upside)
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.66%
12-Months-Change
Fundamentals
Return on Equity
8.17%
Trailing 12-Months
Asset Growth
-2.15%
Trailing 12-Months
Company Description
Wuxi Biologics (Cayman)
WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the People's Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine CDMO and related business; and material supplier activities. WuXi Biologics (Cayman) Inc. has strategic partnership with ImmuneOncia Therapeutics, Legochem Biosciences Inc, Worg Pharma, OncoC4, and Exelixis Inc. The company was incorporated in 2014 and is headquartered in Wuxi, China.
---
2269 Company Deck
---
2269 Earnings Call
Q4 2025
0:00 / 0:00
---
2269 Stock 12 Month Forecast
Average Price Target
HK$31.57
▲(64.23% Upside)
Technical Analysis
Ping An Insurance Company of China
―
Sino Biopharmaceutical
―
CSPC Pharmaceutical Group
―
Luye Pharma Group
―
China Resources Pharmaceutical Group Ltd.
―
Best Analysts Covering 2269
1 Year
1 Year Success Rate
3/6 ratings generated profit
1 Year Average Return
+12.38%
reiterated a buy rating 18 days ago
Copying Jialin Zhang's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +12.38% per trade.
---